PRISMAP in Nantes

 

This rich one-day PRISMAP public event included news about PRISMAP, reports by PRISMAP users about their projects and scientific sessions about radiochemistry and nuclear medicine made in Nantes.

For the first part, we had the pleasure to welcome five of our users to listen at their innovative and original results obtained thanks to the support and supply of radionuclides from PRISMAP’s partner institutes. Dr Margarita Kirienko (Fondazione IRCCS Instituto Nazionale dei Tumori, Milano, Italy) presented the results she obtained with the use of Tb-161 in view of treatment of prostate cancer. Dr Mylene Richard and Dr Bertrand Kuhnast (CEA, Service Hospitalier Frédéric Joliot, Orsay, France) presented new results related to their ScandAl project on Sc-43 antibody -fragment labelling. Dr Eleni Gourni (Universitätklinik für Nuklearmedizin, Bern, Switzerland) presented ground-breaking development in theranostics using scandium radionuclides. Dr Filipe Elvas (University of Antwerp, Belgium) presented the results from its two projects involving At-221 and Cu-67 provided by PRISMAP both aiming in improving the theranostic approach. Dr Clement Morgat (University of Bordeaux, France) showed new results obtained using Tb-161 and zebrafish embryos as a novel model to evaluate the efficacy of short-range emitters used for targeted radionuclide therapy.

For the second and third part of our public event, you can download the presentations directly from the agenda below.

Agenda

8.30 Reception
Part 1 – PRISMAP news for the user community
Chairs: Charlotte Duchemin – CERN, Anne Le Pennec – ARRONAX
9.00 Welcome and news from PRISMAP
9.15 Towards 161Tb-PSMA cell targeting treatment of prostate cancer biochemical recurrence: Comparison with 177Lu-PSMA Dr. Margarita Kirienko – Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (remote)
9.45 ScandAL: Scandium-43 Antibody-fragment Labelling Mylène Richard – CEA, Service Hospitalier Frédéric Joliot, Orsay, France
10.15 Radioligand Development for the Gastrin Releasing Peptide Receptor Targeting using the Theranostic Pair 44/47Sc Dr Eleni Gourni – Universitätklinik für Nuklearmedizin, Bern
10.45 Coffee break
11.00 Improved FAP-radiotheranostics for personalized cancer treatment with At-211 & Theranostic targeting of fibroblast activation protein (FAP) with gold nanoparticles decorated with FAPI fragments with Cu-67 Prof. Filipe Elvas – University of Antwerp (remote)
11.30 Zebrafish embryo as a novel model to evaluate the efficacy of short-range emitters used for targeted radionuclide therapy Dr Clément Morgat – University of Bordeaux (remote)
Part 2 – Radiochemistry made in Nantes
Chairs: Ferid Haddad, Anne Le Pennec – ARRONAX
12.00 Is astatine the next workhorse of targeted alphatherapy? Pluridisciplinary perspectives François Guérard – CRCI2NA lab, Nantes Université
12.30 How chemical simulations can help driving new radiolabelling strategy? Samuel Mador – CEISAM lab, Nantes Université
13.00 Lunch break
Part 3 – Nuclear medicine, from preclinic to bedside
Chairs: Ferid Haddad, Anne Le Pennec – ARRONAX
14.15 The contribution of nuclear medicine to haematology Françoise Kraeber Bodéré – University Hospital of Nantes
14.35 The theranostic approach “à la Nantaise” Caroline Bodet-Milin or Clément Bailly – University Hospital of Nantes
14.55 Developing an animal model for studying alphatherapy of neuroendocrine tumours Alexandre Lugat – CRCI2NA lab, Nantes Université
15.15 Brain intratumoral At-211 radiotherapy targeting syndecan-1 leads to durable glioblastoma remission and immune memory in female mice Michel Chérel – CRCI2NA lab, Nantes Université
15.35 Advanced image analysis in nuclear medicine: an illustration from Nantes Thomas Carlier – University Hospital of Nantes
15.55 Coffee break
16.10 PET imaging and targeted alpha therapy in a multiple myeloma mouse model Sébastien Gouard – CRCI2NA lab, Nantes Université
16.30 Review on the XEMIS2 camera installation progress at the University Hospital of Nantes Nicolas Beaupère – Subatech lab, Nantes Université
16.50 From preclinical work to clinical trials: the Nantes experiences Mickaël Bourgeois – University Hospital of Nantes
17.10 Wrap-up and conclusions Ferid Haddad – ARRONAX
17.30 End of the event
 

Please fill this form to register for the PRISMAP public event

Processing...

Wednesday 18 September 2024
8.30—17.30
Hosted by PRISMAP partner ARRONAX at the Institut de Recherche en Santé – Nantes Université
CHU Nantes
Building Jean Monnet
30 Boulevard Jean Monnet,
44000 Nantes
Ground-floor conference room
Desc 2
Desc 3
In-person registration closed on 7 September 2024, you can still register to attend the meeting online

The meeting can be attended in-person or remotely.